Treatment of mild to moderate forms of acne vulgaris.
Composition:
1 g of gel contains 0.5 mg of isotretinoin. The preparation contains butylhydroxytoluene.
Action:
A topical preparation from the retinoid group. It regulates the growth and differentiation of the epidermis. Isotretinoin administered topically probably acts as tretinoin. Tretinoin stimulates mitosis in epidermal cells, reduces cellular intercellular cohesion in the stratum corneum and affects the hyperkeratosis characteristic of common acne. Supporting exfoliation of the epidermis, it prevents the formation of skin changes. Tretinoin mediates the production of sebaceous cells of the epidermis with less cohesiveness and as a result it probably stimulates the process of removing comedones and prevents the formation of new comedones.
Contraindications:
Hypersensitivity to isotretinoin or other components of the drug. It should not be used in women who are pregnant or planning to become pregnant or who are breast-feeding.
Precautions:
Avoid contact of the gel with eyes, mucous membranes, mouth and damaged or irritated skin. Care should be taken that the gel does not accumulate in the folds of the skin, especially on the neck, the wings of the nose. The preparation should be avoided in patients with a history of epithelial epithelium. Places on the skin treated with gel should be protected from sunlight. If sunlight can not be avoided, products with UV filters and protective clothing should be used on the skin. Do not use in patients with sunburn, because the skin may be more sensitive to sunlight. Avoid artificial sources of UV radiation (quartz lamps, solariums). The product is not intended for use in children (common acne rarely occurs before puberty). Elderly patients are not recommended (common acne is not present in this age group). Due to the content of butylhydroxytoluene, the preparation may cause a local skin reaction (eg contact dermatitis) or irritation of eyes and mucous membranes.
Pregnancy and lactation:
It should not be used in women who are pregnant or planning to become pregnant or breastfeeding. If the patient becomes pregnant during treatment with the preparation, treatment should be discontinued immediately. In humans, isotretinoin, when used in a form with general action, works teratogenically. It has not been established whether isotretinoin is excreted in breast milk.
Side effects:
Burning, redness and itching of the skin, erythematous changes and exfoliation may occur. Usually, these are transient symptoms, but if their intensity increases, the gel should be used less frequently and even the treatment should be discontinued for a few days and then the preparation should be used again. However, if the symptoms of irritation increase again, the treatment should not be continued.
Dosage:
Externally, on the skin. Adults: a small amount of gel should be spread on the affected lesions on the skin 1-2 times a day. Before spreading the gel, the skin should be washed and dried. Usually, the effectiveness of treatment can be observed after 6-8 weeks.
(C)
